3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other solid neoplasm
2
Conditions
Breast Neoplasms
20
Carcinoma, Renal Cell
17
Neoplasm Metastasis
15
Carcinoma, Non-Small-Cell Lung
13
Neoplasms
11
Neuroendocrine Tumors
10
Recurrence
8
Lung Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Prostatic Neoplasms
5
Multiple Myeloma
5
Lymphoma, Mantle-Cell
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Kidney Neoplasms
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Follicular
4
Hodgkin Disease
4
Head and Neck Neoplasms
4
Glioblastoma
4
Waldenstrom Macroglobulinemia
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Interventions
Paclitaxel
12
Gemcitabine
9
atezolizumab
8
Carboplatin
8
Bevacizumab
6
tocilizumab
4
navitoclax
4
liposomal doxorubicin
4
Irinotecan
4
Erlotinib Hydrochloride
4
Cetuximab
4
Sunitinib
3
Oxaliplatin
3
Leucovorin
3
Injections
3
Fluorouracil
3
Docetaxel
3
Cyclophosphamide
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
tislelizumab
2
temsirolimus
2
ridaforolimus
2
plocabulin
2
pembrolizumab
2
pazopanib
2
olaparib
2
obinutuzumab
2
linifanib
2
fludarabine
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Solid Tumors
×
Everolimus
×
Clear all
NCT01349296
2016-05-20
BARIS
University of Cologne
Phase 1
Completed
18 enrolled
NCT00586443
2014-11-19
BEP
Duke University
Phase 1
Completed
56 enrolled